• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What NeoGenomics (NEO)'s Raised Guidance Means For Shareholders

    Simply Wall St·10/31/2026 03:41:02
    語音播報
    • NeoGenomics reported third quarter 2026 results with sales of US$209.25 million and a net loss of US$7.55 million, along with raised full year revenue and adjusted EBITDA guidance.
    • The business highlighted strong next generation sequencing and RaDaR ST assay reimbursement progress, while also setting up a CEO transition to Warren Stone in early 2027.
    • Next, investors may consider how NeoGenomics' upgraded guidance and NGS developments relate to the longer term investment narrative.

    Scan beyond NeoGenomics and explore other lab and diagnostics players that could be building similar momentum in testing and reimbursement with a curated set of 34 healthcare AI stocks.

    What Is NeoGenomics' Investment Narrative?

    To own NeoGenomics, you need to buy into a pretty clear idea. This is a cancer testing specialist that is pouring capital into next generation sequencing, minimal residual disease tools like RaDaR ST, and lab automation, while still running at a loss. The latest quarter fits that story. Sales reached US$209.25 million, losses narrowed, and management lifted full year revenue and adjusted EBITDA guidance, which supports the view that demand and execution in core testing lines are holding up in the near term.

    In the short term, the key swing factors are operational efficiency, reimbursement progress, and how quickly NeoGenomics can scale NGS and MRD without burning too much cash. The raised guidance and improving loss profile suggest that current initiatives such as digital pathology and a unified LIMS are starting to matter, even as the business remains unprofitable and relies on higher risk funding. A CEO handoff to Warren Stone in early 2027 adds an extra execution test, on top of richer P/S multiples and recent insider selling.

    That said, sitting behind the stronger quarter and upbeat guidance is a quieter issue that could still unsettle the NeoGenomics story if ...

    There's only one way to know the right time to buy, sell or hold NeoGenomics. Head to Simply Wall St's company report for the latest analysis of NeoGenomics's Fair Value.

    NasdaqCM:NEO 1-Year Stock Price Chart
    NasdaqCM:NEO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate, more optimistic take on NeoGenomics focuses on RaDaR ST and the idea that minimal residual disease testing could reshape earnings power. The most bullish analysts were penciling in about 10.8% annual revenue growth and potential earnings of roughly US$67.1 million by 2029. These projections came before this quarter's results, so your view may shift as fresh numbers meet older assumptions.

    Explore another NeoGenomics fair value estimate, including one that suggests there may be as much as 86% upside from the current price.

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    • A great starting point for your NeoGenomics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
    • See our latest analysis for NeoGenomics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate NeoGenomics' overall financial health at a glance.

    Looking For More Ideas Beyond NeoGenomics?

    NeoGenomics may be on your radar today, but your portfolio will probably benefit from a wider bench of candidates. A focused stock screener helps you quickly surface companies that match the kind of balance sheet strength, income profile, or upside potential you want to research next.

    • If capital preservation and smoother returns matter to you, start by reviewing a group of 30 resilient stocks with low risk scores that score well on resilience and risk controls.
    • Income seekers can zero in on cash generators by scanning a curated set of 5 dividend fortresses that combine higher yields with established payout histories.
    • For those willing to do deeper work on underfollowed opportunities, widen your search with a handpicked pool of 18 high quality undiscovered gems that pair strong fundamentals with relatively low market attention.